Ascorbic Acid Levels in MDS, AML, and CMML Patients

V

Van Andel Research Institute

Status

Completed

Conditions

CMML
AML
MDS
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Chronic Myelomonocytic Leukemia

Treatments

Other: Peripheral blood collection

Study type

Observational

Funder types

Other

Identifiers

NCT03526666
17022 (Registry Identifier)

Details and patient eligibility

About

This study is a non-interventional, specimen collection translational study to evaluate vitamin C levels in the peripheral blood of Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), or Chronic Myelomonocytic Leukemia (CMML) patients.

Full description

It has previously been established that hematological cancer patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) often exhibit severe vitamin C deficiency from a cohort of patients in Copenhagen. In this study, the investigators aim to determine if those results are conserved in another population/geographical location.

Enrollment

50 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients actively receiving treatment for acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML).
  • Patients diagnosed with AML, MDS, or CMML and are treatment naïve.
  • Patients who are 18 years old or older.

Exclusion criteria

  • Patients deemed as too ill to participate as determined by the clinical investigator.
  • Non-English speaking patients
  • Patients unable to provide informed consent.

Trial design

50 participants in 1 patient group

AML, MDS, and CMML patients
Description:
Patients with a diagnosis of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML).
Treatment:
Other: Peripheral blood collection

Trial documents
1

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems